Open AccessA novel oncoprotein Pirh2: rising from the shadow of MDM2
Author(s) -
Wang Zhihao,
Yang Bo,
Dong Lanlan,
Peng Biwen,
He Xiaohua,
Liu Wanhong
Publication year - 2011
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2011.01899.x
Subject(s) - mdm2 , ubiquitin ligase , carcinogenesis , cancer , cancer research , ubiquitin , biology , dna damage , microbiology and biotechnology , computational biology , bioinformatics , genetics , apoptosis , dna , gene
Pirh2 (p53‐induced RING‐H2) is an E3 ubiquitin ligase that can target p53 for degradation and thereby repress a diverse group of biological activities regulated by p53. Notably, Pirh2, rather than MDM2, is the primary degrader of active p53 under conditions of DNA damage. Moreover, Pirh2 is highly expressed in multiple cancer cell lines regardless of p53 status. Recent research has shown that Pirh2 is involved in many signalling pathways related to the genesis and evolution of cancer. This review aims to summarize a comprehensive picture of the role of Pirh2 in cellular processes and its significance to tumorigenesis. Furthermore, this review focuses on its potential role as a cancer therapeutic target. ( Cancer Sci 2011; 102: 909–917)